^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    B-Vaxx

    i
    Other names: B-Vaxx, B Vaxx, anti-HER2-B-cell-peptide-cancer-vaccine, MVF-HER-2(597-626)/MVF-HER-2 (266-296) Peptide Vaccine
    Associations

    News

    Trials
    Company:
    Imugene
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    8ms
    Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=65, Completed, Robert Wesolowski | Recruiting --> Completed | N=100 --> 65 | Trial completion date: Dec 2023 --> Nov 2022 | Trial primary completion date: Dec 2023 --> Nov 2022
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 expression • EGFR expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx
    1year
    Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Pravin Kaumaya | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 expression • EGFR expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx
    over2years
    Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Pravin Kaumaya | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 expression • EGFR expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • B-Vaxx